Corgenix AspirinWorks(R) Test Now Offered Through Quest Diagnostics

Main Category: Pharma Industry / Biotech Industry
Also Included In: Blood / Hematology;  Cardiovascular / Cardiology;  Stroke / Neuroprotection
Article Date: 04 Feb 2008 - 8:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced that its AspirinWorks(R) test is available to physicians and other laboratories through Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services.

"This arrangement with Quest Diagnostics is great news for the increasing number of physicians and labs wanting to offer the AspirinWorks test," said Douglass Simpson, Corgenix' President and Chief Executive Officer. "Some of the nation's most prominent labs are now routinely running this important test, which determines if aspirin is eliciting an effect."

AspirinWorks is a simple urine test that determines the effect of aspirin on platelets by measuring the level of thromboxane production (aspirin's target). The higher the levels of thromboxane, the stickier the blood platelets, and the less impact the aspirin is having. This crucial information allows physicians to individualize a patient's therapy.

Unlike other tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks test only requires a urine sample that can be obtained in any doctor's office, making the test easy for both physician and patient.

The AspirinWorks test, which was launched in 2007 following FDA 510(k) clearance, is now available nationwide through a growing list of national and regional clinical laboratories. Simpson said additional supporting clinical data and scientific articles scheduled for publication in 2008 will further enhance the science and clinical validation behind aspirin effect testing.

The AspirinWorks test is an enzyme-linked immunoassay (ELISA) to determine levels of 11-Dehydro Thromboxane B2 (11dhTxB2) in human urine, which aids in the qualitative detection of aspirin effect in apparently healthy individuals post ingestion. The test targets a potential U.S. market of over 60 million individuals and a potential global market exceeding 200 million individuals.

The AspirinWorks product will be featured at several upcoming scientific meetings, including the American College of Osteopathic Family Physicians in March, the American College of Cardiology in March and the American College of Physicians in May.

More information is also available at http://www.aspirinworks.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at http://www.corgenix.com.

Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe," "estimate," "project," "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Note: The "2" in Thromboxane B2 (11dhTxB2) is subscript. This may not appear properly in some systems.

http://www.corgenix.com